Related Experiment Video
Updated: Aug 6, 2026

12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Non-lethal junctional epidermolysis bullosa in a dog
The British Journal of Dermatology
|February 12, 1998
Summary
A dog diagnosed with a non-lethal subtype of junctional epidermolysis bullosa (JEB) shows skin fragility and blistering. This case offers a potential animal model for studying JEB and gene therapy approaches.
Area of Science:
- Veterinary Dermatology
- Genetics
- Molecular Biology
Background:
- Junctional epidermolysis bullosa (JEB) is a group of rare inherited disorders characterized by skin fragility and blistering.
- Non-lethal subtypes of JEB are less common and their pathophysiology is not fully understood.
- Animal models are crucial for understanding disease mechanisms and developing therapeutic strategies.
Observation:
- A 4-year-old mongrel dog presented with congenital skin erosions, atrophy, alopecia, and dystrophic nails.
- Histopathology revealed subepidermal blisters, with electron microscopy localizing the cleavage to the lamina lucida.
- Immunohistochemistry showed positive expression of laminin 5, BPAG2, integrin-alpha 6, and type VII collagen in the dog's skin.
Findings:
- The clinical, ultrastructural, and immunohistochemical findings confirmed a diagnosis of non-lethal junctional epidermolysis bullosa (JEB) in the dog.
- This represents the first documented case of non-lethal JEB in a canine.
- The identified biomarkers are consistent with JEB, specifically involving the basement membrane zone.
Implications:
- This canine case offers a potential animal model for investigating the pathophysiology of non-lethal JEB.
- The findings may contribute to the development of gene therapy strategies for epidermolysis bullosa.
- Further research can elucidate the phenotype, prognosis, and therapeutic targets for human JEB.
More Related Videos
Related Concept Videos
Nucleotide Excision Repair
Overview
Long-patch Base Excision Repair
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
Clinical Applications of Epidermal Stem Cells
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

